NYSE:GLS

Gelesis (GLS) Stock Price, News & Analysis

Notice: This company has been marked as potentially delisted and may not be actively trading.
Today's Range
N/A
50-Day Range
$0.11
$0.33
52-Week Range
N/A
Volume
185,100 shs
Average Volume
386,034 shs
Market Capitalization
$11.63 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
N/A
GLS stock logo

About Gelesis Stock (NYSE:GLS)

Gelesis Holdings Inc., a commercial stage biotherapeutics company, developing a biomimicry to treat the genesis of obesity and GI-related chronic diseases. The company also provides PLENITY, an orally administered, non-stimulant, and non-systemic aid for weight management. In addition, it offers a product for obesity and overweight and a pipeline with potential therapies for non-alcoholic fatty liver disease/non-alcoholic steatohepatitis, type 2 diabetes, and GS500 for Functional Constipation. Gelesis Holdings Inc. was incorporated in 2006 and is headquartered in Boston, Massachusetts.

GLS Stock News Headlines

Gelesis Holdings Inc GLSHQ
top AI stock (it’s not MSFT, GOOGL, AMZN or AAPL)
AI was by far the biggest tech investing trend right now. But Ross Givens says the #1 artificial intelligence stock[/lin] is NOT Microsoft, Google, Amazon or Apple. Nope — his research is pointing to a tiny, under-the-radar stock that’s trading for just a few dollars right now… And could soon shoot to the moon, handing early investors a windfall.
GLS Gelesis Holdings, Inc.
top AI stock (it’s not MSFT, GOOGL, AMZN or AAPL)
AI was by far the biggest tech investing trend right now. But Ross Givens says the #1 artificial intelligence stock[/lin] is NOT Microsoft, Google, Amazon or Apple. Nope — his research is pointing to a tiny, under-the-radar stock that’s trading for just a few dollars right now… And could soon shoot to the moon, handing early investors a windfall.
Gelesis Reports Third Quarter 2022 Results
Gelesis Holdings Inc GLS Stock Analysis
See More Headlines
Receive GLS Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Gelesis and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Today
4/23/2024
Fiscal Year End
12/31/2024

Industry, Sector and Symbol

Sector
Medical
Industry
Pharmaceutical preparations
Sub-Industry
N/A
Phone
N/A
Fax
N/A
Employees
2
Year Founded
N/A

Profitability

Net Income
$-56,030,000.00
Net Margins
-221.38%
Pretax Margin
-214.62%

Debt

Sales & Book Value

Annual Sales
$25.77 million
Book Value
($0.34) per share

Miscellaneous

Free Float
64,606,000
Market Cap
$11.63 million
Optionable
Not Optionable
Beta
0.88
The Next 7 Blockbuster Stocks for Growth Investors Cover

Wondering what the next stocks will be that hit it big, with solid fundamentals? Click the link below to learn more about how your portfolio could bloom.

Get This Free Report

Key Executives

  • Mr. Yishai Zohar (Age 59)
    Founder, Pres, CEO & Director
    Comp: $689.95k
  • Mr. Elliot Maltz CPA (Age 37)
    CFO & Treasurer
    Comp: $486.26k
  • Dr. David Pass Pharm.D. (Age 53)
    COO & Chief Commercial Officer
  • Dr. Elaine Chiquette Pharm.D. (Age 55)
    Chief Scientific Officer
  • Ms. Joy Bauer M.S.
    MS, RDN, Chief Nutrition Officer of Plenity

This page (NYSE:GLS) was last updated on 4/23/2024 by MarketBeat.com Staff

From Our Partners